药品注册受理信息查询结果
http://www.hotlek.ru/eng/ingavirin Ingavirin® - drug destined for new direction in the flu therapy Three months ago one of the largest Russian pharmaceutical company Valenta have launched new antiviral product. Ingavirin® – original innovative domestic product developed by Russian scientists including military virologists under supervision of the Chief Therapist of Russian Federation, Academician of RAS Alexander G. Chuchalin. Product was registered in August, 2008 and was presented in the market in January 2009. Registration certificate LSR – 006330/08. High antiviral efficacy was showed in the trials in vitro and in vivo to the A grippe (subtypes H3N2, H1N1, H5N1), experimental B virus, adenoviruses. Ingavirin® suppresses virus replication in the nuclear stage of the cycle. Antiviral efficacy of Ingavirin® to A virus is realized by the inhibition of the newly synthesized viral NP-protein migration from cytoplasm to nucleus, which is necessary for the infectious process in the infected cells. In distinction from the existing products aimed for the flu treatment Ingavirin is operating to the new protein target - NP-protein. Ingavirin is the only antiviral product providing cell protection by the abruption of the virus multiplication. Expectancy of the resistance evolution is extremely small. Clinical trials of Ingavirin® within I, II, III phases of trials were fulfilled in the specialized research centers of Russia under guidance of Professor of the Ivanovsky Scientific Institute of Virology Kolobukhina L.V. High curative efficacy and safety was proven. Trials were performed in the scientific institutions of Russia: - Ivanovsky Scientific Institute of Virology - 48th Central research Institute of The Ministry of Defense of Russia - Gamaleya Scientific Institute of Epidemiology and Microbiology / Russian Academy of Medicine - Medical Center of the Moscow Government and Mayor Administration - St.-Peterburg Institute of Pharmaceuticals - et al. Therefore there is an efficient product in the market possessing high antiviral activity in regard to the known strains of the A and B flu with high safety profile. Nowadays the company has started trials of the prophylactic dosage of Ingavirin®. Those trials are to be completed in 2010. Gennadiy G. Onishchenko, Russian chief public health officer, Head of the Federal Service for Surveillance in the Sphere of Consumer Rights Protection and Human Well-Being: “Ingavirin® is included in to the list of recommended medicines for treatment of flu, including the famous A/H1N1 thanks to prompt clinical trials conducted by Federal Enterprise “48th Central research Institute of The Ministry of Defense of Russia”. 从读音上看，应该是 ETRAVIRINE，也有翻译成伊曲韦林的，2008年1月美国上市，可以自己查一下。 |